{
  "id": 93738,
  "title": "FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients",
  "url": "https://urgent.news/2026/08/03/fda-expands-pluvicto-label-making-it-available-to-most-metastatic",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-03T15:26:14.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-expands-pluvicto-label-making-it-available-to-most-metastatic-prostate-cancer-patients/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the eligible patient population for Pluvicto, according to a Novartis",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}